Trials / Terminated
TerminatedNCT00898547
Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB 30107
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 47 (estimated)
- Sponsor
- Alliance for Clinical Trials in Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.
Detailed description
OBJECTIVES: * Determine if elevated levels of thrombospondin I serum levels, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin portend a poor prognosis in patients with unresectable malignant mesothelioma treated with vatalanib on protocol CALGB-30107. * Determine if elevated levels of thrombospondin I serum levels, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin correlate with response or stable disease in these patients. OUTLINE: Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA). PROJECTED ACCRUAL: A total of 47 specimens will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | immunoenzyme technique | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-03-01
- Completion
- 2015-08-01
- First posted
- 2009-05-12
- Last updated
- 2019-01-24
Source: ClinicalTrials.gov record NCT00898547. Inclusion in this directory is not an endorsement.